RANBAXY TO CONDUCT NEW GENERIC HIV DRUG STUDIES

Generic Line
A A

Ranbaxy Laboratories plans to conduct new clinical studies in North America for its generic antiretroviral fixed-dose combination (FDC) HIV treatments to definitively establish their bioequivalence, company officials said.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $10.00